SUBSCRIBE
SUBSCRIBE
News   Drug Development

ERYtech Pharma: FDA Grants Orphan Drug Designation to GRASPA(R) for Treatment of Acute Lymphoblastic Leukemia

January 26, 2010 | 
1 min read
LYON, France & PHILADELPHIA--(BUSINESS WIRE)--ERYtech Pharma announces that FDA has granted an Orphan Drug Designation (ODD) for GRASPA®, the company’s lead product in Acute Lymphoblastic Leukaemia.
Clinical research Phase I Europe
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
IN PARTNERSHIP WITH ECLIPSEBIO
The mRNA Revolution You Haven’t Heard About: From Cystic Fibrosis to Personalized Cancer Vaccines
July 10, 2025
 · 
1 min read
 · 
Lori Ellis
AbbVie's office in South San Francisco, California
Cancer
AbbVie Scoops Up Ichnos Glenmark’s Lead Myeloma Antibody for Nearly $2B
July 10, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Business consultant. Hands help a businessman is falling from a graph vector
Rare diseases
Ultragenyx, Mereo Plummet After Late-Stage Trial for Rare Genetic Disorder Appears To Fall Short
July 10, 2025
 · 
2 min read
 · 
Tristan Manalac
FDA signage at its headquarters in Maryland
ALS
ALS Community Petitions FDA To Reconsider BrainStorm’s NurOwn, Pointing to Recent Survival Data
July 8, 2025
 · 
3 min read
 · 
Heather McKenzie